52
Participants
Start Date
September 16, 2019
Primary Completion Date
April 16, 2020
Study Completion Date
April 24, 2020
BI 1265162
Inhalation solution
Placebo
Inhalation solution
Brussels - UNIV UZ Brussel, Brussels
UZ Leuven, Leuven
Charité - Universitätsmedizin Berlin, Berlin
Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh
Virginia Commonwealth University Health Systems, Richmond
The University of North Carolina at Chapel Hill, Chapel Hill
Medical University of South Carolina, Charleston
HOP Perharidy, Roscoff
Medizinische Hochschule Hannover, Hanover
Nemours Children's Hospital, Orlando
HOP Arnaud de Villeneuve, Montpellier
Universitätsklinikum Gießen und Marburg GmbH, Giessen
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen
Riley Hospital for Children at Indiana University Health, Indianapolis
HOP Lyon Sud, Pierre-Bénite
Universitätsklinikum Tübingen, Tübingen
HOP Robert Debré, Paris
University of Texas Southwestern Medical Center, Dallas
HOP Cochin, Paris
University of Washington, Seattle
St. Paul's Hospital, Vancouver
Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal
Hospital Vall d'Hebron, Barcelona
Sahlgrenska US, Göteborg, Gothenburg
Stockholm CF-Center , B59, Huddinge Universitetssjukhus, Stockholm
Royal Brompton Hospital, London
Lead Sponsor
Boehringer Ingelheim
INDUSTRY